KNX-100 is under clinical development by Kinoxis Therapeutics and currently in Phase I for Opium (Opioid) Addiction. According to GlobalData, Phase I drugs for Opium (Opioid) Addiction have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KNX-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KNX-100 overview

KNX-100 is under development for the treatment of alcohol addiction and drug (methamphetamine, cocaine and opiod) addiction, aggression and agitation. It is administered through oral route. The drug candidate targets non-peptide oxytocin receptor (OTR).

Kinoxis Therapeutics overview

Kinoxis Therapeutics is engaged in development of a range of novel therapeutic compounds for the treatment of addiction and substance use disorders. The company is headquartered in Australia.

For a complete picture of KNX-100’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.